Founded in 2010, Trxade Group is comprised of four synergistic operating platforms the Trxade B2B trading platform with 12,100 registered pharmacies, Integra Pharma Solutions virtual wholesale division, affordable telehealth services through its Bonum Health platform and the coordination of a nationwide distribution network through independent pharmacies or mail order delivery via its DelivMeds app. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. ( Nasdaq: MEDS) is an integrated drug procurement, delivery and healthcare platform that fosters price transparency and thereby improves profit margins for both buyers and sellers of pharmaceuticals.
Negative test results do not rule out infection and follow-up testing with molecular diagnostics should be considered in patients with signs and symptoms or recent exposure to the virusĪbout Trxade Group, Inc. Headquartered in Tampa, Florida, Trxade Group, Inc. The novel Antibody Rapid Test Kit begins working from blood drawn with a single pinprick, providing results within 15 minutes
#Trxade integration guide professional
Tests are not meant for home use and should be performed under the supervision of a qualified healthcare professional This rapid immunochromatography test provides qualitative detection of specific antibodies (IgM and IgG) found to match those of COVID-19 and is not meant solely for diagnostic purposes Features of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit: The strategic partnership entered into by Trxade aims to scale distribution efforts to up to 1,000,000 units in order to supply healthcare facilities and provider offices nationwide to assist with providing value-based care. Trxade has announced 20,000 units available for purchase as pre-orders as soon as April 10, 2020. The rapid test is intended to be administered at the point of care with no additional instrumentation needed. Currently, the test is intended to aid in presenting a qualitative overview of antibody presence in patients who have possibly been infected by the Coronavirus (COVID-19). Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or when there are no adequate, approved, and available alternatives.įiling the EUA has dual purposes first it serves as notification to FDA that Trxade Group will be distributing the test and secondly, if the EUA is approved, it enables Trxade Group to market the product for diagnostic use. Food and Drug Administration (FDA) in collaboration with its partnered manufacturer of the SARS-CoV-2 IgM/IgG Antibody Rapid Test Kit. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform, announces its wholly-owned subsidiary, Integra Pharma Solutions, has filed for an Emergency Use Authorization (EUA) with the U.S. TAMPA, FL, Ap(GLOBE NEWSWIRE) - Trxade Group, Inc.
0 kommentar(er)
